September 11, 2026

The Listing Department,
National Stock Exchange of India Limited
NSE Symbol: **VIJAYA**

The Corporate Relations Department,
BSE Limited
BSE Scrip Code: **543350**

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on Friday, September 11, 2026

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") as amended from time to time.

We hereby inform you that, the Board of Directors of the Company at their meeting held today i.e., on **Friday, September 11, 2026,** has, inter-alia, considered and approved the acquisition of the integrated diagnostic business undertaking of Arya Wellness Centre, on a slump sale basis, from NEMRIL HRPL JV (North Eastern Medical Research Institute Limited – Hexagon Research Private Limited JV), subject to the terms and conditions set out in the Business Transfer Agreement ("BTA").

The detailed disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 is enclosed as **Annexure-A.**

The Board Meeting commenced at 05:45 p.m. and concluded at 06:05 p.m.

Kindly take the same on record.

Thanking You.

Yours Faithfully
For **Vijaya Diagnostic Centre Limited**

KOLUKULURI APPALA NARASIMHA RAJU
Digitally signed by KOLUKULURI APPALA NARASIMHA RAJU
Date: 2026.09.11 18:53:22 +05'30'

Narasimha Raju K A
Chief Financial Officer

Encl.: as above

Annexure–A

Disclosures under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026

Sr. No.	Particulars / Disclosure Requirement	Details / Disclosures
1.	**Name of the target entity, details in brief such as size, turnover etc.**	**Target Business Undertaking:** Acquisition of the integrated diagnostic business undertaking of **Arya Wellness Centre** on a slump sale basis from NEMRIL HRPL JV (North Eastern Medical Research Institute Limited – Hexagon Research Private Limited JV). Turnover/Size: The turnover of the target business for the preceding financial year (FY 2025-26) was ₹ 26.95 Crores.
2.	**Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".**	The proposed transaction does not constitute a related party transaction. The promoter, promoter group, and group companies of the Company do not hold any interest in the seller entity. Consequently, the requirement of an arm's length assessment is not applicable.
3.	**Industry to which the entity/business being acquired belongs.**	The target business undertaking operates within the Healthcare and Diagnostics industry.
4.	**Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).**	The acquisition is aligned with the Company's strategic objective of expanding its diagnostic business into Assam and strengthening its presence in North-East India.

Sr. No.	Particulars / Disclosure Requirement	Details / Disclosures
5.	**Brief details of any governmental or regulatory approvals required for the acquisition.**	The consummation of the transaction remains subject to requisite statutory and regulatory approvals from the relevant governmental authorities.
6.	**Indicative time period for completion of the acquisition.**	The transaction is tentatively expected to be completed within 90 days, or such extended period as may be mutually agreed upon by the parties, subject to the fulfilment of customary conditions precedent specified in the Business Transfer Agreement (BTA).
7.	**Consideration – whether cash consideration or share swap or any other form and details of the same.**	Cash Consideration.
8.	**Cost of acquisition and/or the price at which the business/shares are acquired.**	A total lump-sum purchase consideration of ₹ 46.20 Crores (Rupees Forty-Six Crores and Twenty Lakhs Only) is payable pursuant to the terms of the Business Transfer Agreement, subject to customary closing working capital adjustments.
9.	**Percentage of shareholding / control acquired and / or number of shares acquired.**	**Not applicable.** The transaction entails the acquisition of a business undertaking on a slump sale basis as a going concern, rather than the acquisition of equity shares. Post-completion, the Company shall assume 100% operational control over the said business undertaking.
10.	**Brief background of the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).**	The target is a B2C-focused integrated diagnostic business providing comprehensive pathology and radiology services. It maintains an operational presence in Guwahati, Assam, India. **Historical Turnover (Last 3 Financial Years):** • FY 2025-26: ₹ 26.95 Crores • FY 2024-25: ₹ 25.61 Crores • FY 2023-24: ₹ 22.99 Crores